keyword
MENU ▼
Read by QxMD icon Read
search

PFS

keyword
https://www.readbyqxmd.com/read/29779086/retrospective-study-of-nivolumab-for-patients-with-recurrent-high-grade-gliomas
#1
Megan Mantica, Ashley Pritchard, Frank Lieberman, Jan Drappatz
INTRODUCTION: Patients with recurrent high-grade gliomas (HGG) have limited treatment options. HGG utilize the PD-1 pathway to evade immune responses. Checkpoint inhibitors have demonstrated safety and clinical activity in patients with recurrent glioblastoma. We explored the efficacy of nivolumab in recurrent HGG with a primary objective of progression free survival (PFS) and overall survival (OS). METHODS: We retrospectively analyzed HGG patients treated with nivolumab in our institution...
May 19, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29778787/efficacy-of-palbociclib-combinations-in-hormone-receptor-positive-metastatic-breast-cancer-patients-after-prior-everolimus-treatment
#2
Ajay Dhakal, Christina M Matthews, Ellis Glenn Levine, Kilian Elizabeth Salerno, Fan Zhang, Kazuaki Takabe, Amy P Early, Stephen B Edge, Tracy O'Connor, Thaer Khoury, Jessica S Young, Mateusz Opyrchal
PURPOSE: Outcome data on hormone receptor positive (HR+ ), human epidermal growth factor receptor 2 (HER2) nonamplified (HER2- ) metastatic breast cancer (MBC) treated with palbociclib after treatment with everolimus are lacking. The PALOMA-3 trial, showing benefit of palbociclib plus fulvestrant compared to fulvestrant alone in HR+ HER2- MBC after progression while receiving endocrine therapy excluded women previously treated with everolimus. The objective of this study was to examine outcomes of HR+ HER2- MBC with prior exposure to everolimus while receiving palbociclib-based therapy...
April 28, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29778569/mevalonate-pathway-blockage-enhances-the-efficacy-of-mtor-inhibitors-with-the-activation-of-retinoblastoma-protein-in-renal-cell-carcinoma
#3
Nobuhisa Hagiwara, Motoki Watanabe, Mahiro Iizuka-Ohashi, Isao Yokota, Seijiro Toriyama, Mamiko Sukeno, Mitsuhiro Tomosugi, Yoshihiro Sowa, Fumiya Hongo, Kazuya Mikami, Jintetsu Soh, Akira Fujito, Hiroaki Miyashita, Yukako Morioka, Tsuneharu Miki, Osamu Ukimura, Toshiyuki Sakai
Renal cell carcinoma (RCC) is the most common malignancy of kidney and remains largely intractable once it recurs after resection. mTOR inhibitors have been one of the mainstays used against recurrent RCC; however, there has been a major problem of the resistance to mTOR inhibitors, and thus new combination treatments with mTOR inhibitors are required. We here retrospectively showed that regular use of antilipidemic drug statins could provide a longer progression free survival (PFS) in RCC patients prescribed with an mTOR inhibitor everolimus than without statins (median PFS, 7...
May 17, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29777975/geriatric-analysis-from-prodige-20-randomized-phase-ii-trial-evaluating-bevacizumab-chemotherapy-versus-chemotherapy-alone-in-older-patients-with-untreated-metastatic-colorectal-cancer
#4
T Aparicio, O Bouché, E Francois, F Retornaz, E Barbier, J Taieb, S Kirscher, P-L Etienne, R Faroux, F Khemissa Akouz, F El Hajbi, C Locher, Y Rinaldi, T Lecomte, S Lavau-Denes, M Baconnier, A Oden-Gangloff, D Genet, L Bedenne, E Paillaud
BACKGROUND: Older patients have frailty characteristics that impair the transposition of treatment results found in younger patients. Predictive factors are needed to help with treatment choices for older patients. The PRODIGE 20 study is a randomized phase II study that evaluated chemotherapy associated with bevacizumab (BEV) or not (CT) in patients aged 75 years or older. PATIENTS AND METHODS: Patients underwent a geriatric assessment at randomization and at each evaluation...
May 16, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29777418/earliest-radiological-progression-in-glioblastoma-by-multidisciplinary-consensus-review
#5
Roelant S Eijgelaar, Anna M E Bruynzeel, Frank J Lagerwaard, Domenique M J Müller, Freek R Teunissen, Frederik Barkhof, Marcel van Herk, Philip C De Witt Hamer, Marnix G Witte
BACKGROUND: Detection of glioblastoma progression is important for clinical decision-making on cessation or initiation of therapy, for enrollment in clinical trials, and for response measurement in time and location. The RANO-criteria are considered standard for the timing of progression. To evaluate local treatment, we aim to find the most accurate progression location. We determined the differences in progression free survival (PFS) and in tumor volumes at progression (Vprog) by three definitions of progression...
May 18, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29775809/transient-asymptomatic-pulmonary-opacities-during-osimertinib-treatment-and-its-clinical-implication
#6
Hansang Lee, Ho Yun Lee, Jong-Mu Sun, Se-Hoon Lee, Youjin Kim, Song Ee Park, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
INTRODUCTION: Osimertinib is an oral, potent, irreversible 3rd generation EGFR tyrosine kinase inhibitor (TKI) approved for the treatment of T790M positive non-small cell lung cancer (NSCLC) patients who failed 1st or 2nd generation EGFR TKIs. Interstitial lung disease (ILD) is a rare complication with osimertinib, occurring in 1-3%. Recently, relatively high incidence of transient asymptomatic pulmonary opacities (TAPOs) which are different from ILD has been described. However, its clinical implication has not been fully determined yet...
May 15, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29775808/phase-ii-study-of-maintenance-pembrolizumab-in-patients-with-extensive-stage-small-cell-lung-cancer-sclc
#7
Shirish M Gadgeel, Nathan A Pennell, Mary Jo Fidler, Balazs Halmos, Philip Bonomi, James Stevenson, Bryan Schneider, Ammar Sukari, Jaclyn Ventimiglia, Wei Chen, Cathy Galasso, Antoinette Wozniak, Julie Boerner, Gregory P Kalemkerian
PURPOSE: To assess the efficacy of maintenance pembrolizumab in extensive-stage small cell lung cancer (SCLC) patients, after treatment with platinum/etoposide. PATIENTS AND METHODS: Extensive-stage SCLC patients with a response or stable disease following induction chemotherapy were eligible. Pembrolizumab at a dose of 200 mg IV every 3 weeks was initiated within 8 weeks of the last cycle of chemotherapy. The primary endpoint of the study was progression-free survival (PFS) from study registration, with overall survival (OS) as a key secondary endpoint...
May 15, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29775154/clinical-and-radiological-outcomes-of-proactive-gamma-knife-surgery-for-asymptomatic-meningiomas-compared-with-the-natural-course-without-intervention
#8
Kyung Hwan Kim, So Jeong Kang, Jung-Won Choi, Doo-Sik Kong, Ho Jun Seol, Do-Hyun Nam, Jung-Il Lee
OBJECTIVE This study aimed to verify the effect of proactive Gamma Knife surgery (GKS) in the treatment of asymptomatic meningioma compared with the natural course without any therapeutic intervention. METHODS From January 2006 to May 2017, 354 patients newly diagnosed with asymptomatic meningioma were reviewed and categorized into GKS (n = 153) and observation (n = 201) groups. Clinical and radiological progression rates were examined, and changes in volume were analyzed. RESULTS Clinical progression (i.e...
May 18, 2018: Journal of Neurosurgery
https://www.readbyqxmd.com/read/29774877/-analysis-of-prognostic-factors-for-survival-in-elderly-patients-with-glioma
#9
Jinghui Liu, Miao Lou, Peigang Ji, Chen Li, Fuqiang Feng, Baofu Li, Meng Xu, Guodong Gao, Yan Qu, Liang Wang
To analyze the prognostic factors for survival in elderly patients with glioma.
 Methods: We performed a retrospective analysis of prognostic factors for elderly patients with glioma, who were treated by the same attending doctor during June 2014 and June 2016, to investigate the correlations of the age, dimension of pathology, histological grade, extent of resection, adjuvant therapy, preoperative Karnofsky Performance Scale (KPS) score, postoperative KPS score, molecular markers [isocitrate dehydrogenase-1 (IDH-1), O6-methylguanine DNA-transferase (MGMT), epidermal growth factor receptor (EGFR), Ki-67] with the prognosis...
April 28, 2018: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
https://www.readbyqxmd.com/read/29774874/-survival-analysis-for-high-grade-glioma-patients-who-received-comprehensive-treatment
#10
Guiyun Liu, Rong Jiang, Chenyang Xu, Jiao Zhou, Fengxin Liu, Zhengwen He, Zhigang Liu
To analyze the curative effect and prognostic factors for comprehensive therapy in patients with high-grade glioma.
 Methods: Patients with high-grade glioma (WHO grade III, grade IV) were chosen from July 2008 to May 2016 in the Hunan Cancer Hospital, and a retrospective analysis was performed in 64 patients with complete follow-up data.
 Results: The follow-up time was 3-111 (median 29.5) months, the median overall survival time was 36.00 (95% CI 22.85 to 49.16) months, the median progression-free survival time (PFS) was 21...
April 28, 2018: Zhong Nan da Xue Xue Bao. Yi Xue Ban, Journal of Central South University. Medical Sciences
https://www.readbyqxmd.com/read/29774414/tumoral-cavitation-in-colorectal-cancer-patients-with-unresectable-lung-metastasis-treated-with-bevacizumab-and-chemotherapy
#11
REVIEW
Yu Peng, Ye Chen, Xi Zhang, Yu Yang, Dan Cao, Feng Bi, Zhipi Li, Hongfeng Gou
PURPOSE: Efficacy and the frequency of tumor cavitation have not been investigated in patients with metastatic colorectal cancer (mCRC) and lung metastases (LMs) treated with chemotherapy in combination with bevacizumab. This study was aimed to evaluate the efficacy and safety of bevacizumab for unresectable mCRC with LM and to determine the frequency of tumor cavitation, and its correlation with clinical outcomes in patients receiving bevacizumab plus chemotherapy. METHODS: Patients with mCRC and LMs treated with bevacizumab as first- or second-line therapy at West China Hospital, Sichuan University Cancer Center from September 2010 to November 2016 were included in this retrospective study...
May 17, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29774395/early-versus-late-prophylactic-cranial-irradiation-in-patients-with-extensive-small-cell-lung-cancer
#12
Yi Chen, Jinyu Li, Yibao Zhang, Yi Hu, Guoqing Zhang, Xiang Yan, Zhi Lin, Zhifei Zhao, Shunchang Jiao
OBJECTIVE: Previous studies demonstrated that prophylactic cranial irradiation (PCI) significantly reduced the incidence of brain metastases in patients with extensive disease small cell lung cancer (ED-SCLC). However, the appropriate timing for PCI in treating ED-SCLC is still unclear. This study aimed to compare the effect and safety of early versus late PCI. METHODS: Between November 2011 and July 2016, 103 patients with ED-SCLC were reviewed, receiving appropriate imaging tests to exclude brain metastases prior to cranial irradiation...
May 17, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29774169/phase-2-study-of-everolimus-for-relapsed-or-refractory-classical-hodgkin-lymphoma
#13
Patrick B Johnston, Lauren C Pinter-Brown, Ghulam Warsi, Kristen White, Radhakrishnan Ramchandren
Background: The current standard of care for classical Hodgkin lymphoma (HL) is multiagent chemotherapy with or without radiation. In patients who relapse or fail to respond, additional high-dose chemotherapy with autologous hematopoietic stem cell transplantation (AHSCT) can improve progression-free survival (PFS). Novel therapies are required for patients refractory to chemotherapy and AHSCT. The mammalian target of rapamycin inhibitor everolimus has shown preliminary activity in preclinical models of HL and promising efficacy in patients with relapsed or refractory HL...
2018: Experimental Hematology & Oncology
https://www.readbyqxmd.com/read/29771717/prognostic-predictive-value-of-preoperative-intratumoral-2-deoxy-2-18f-fluoro-d-glucose-uptake-heterogeneity-in-patients-with-high-grade-serous-ovarian-cancer
#14
Shuai Liu, Zheng Feng, Zhaoxia Jiang, Hao Wen, Junyan Xu, Herong Pan, Yu Deng, Lei Zhang, Xingzhu Ju, Xiaojun Chen, Xiaohua Wu
OBJECTIVE: This study aimed to explore the clinical and prognostic significance of pretreatment positron-emission tomography/computed tomography (PET/CT) parameters, especially 2-deoxy-2-(F)fluoro-D-glucose-based heterogeneity, in high-grade serous ovarian cancer (HGSC). MATERIALS AND METHODS: We retrospectively investigated 56 patients with HGSC who underwent PET/CT before primary surgery at our hospital between January 2010 and June 2015. None of these patients received neoadjuvant chemotherapy...
May 16, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29771005/prospective-analysis-of-different-combined-regimens-of-stereotactic-body-radiation-therapy-and-chemotherapy-for-locally-advanced-pancreatic-cancer
#15
Xiaofei Zhu, Dongchen Shi, Fuqi Li, Xiaoping Ju, Yangsen Cao, Yuxin Shen, Fei Cao, Shuiwang Qing, Fang Fang, Zhen Jia, Huojun Zhang
To identify impacts of different combined regimens of stereotactic body radiation therapy (SBRT) and chemotherapy on survival of patients with locally advanced pancreatic cancer (LAPC) and factors correlated with determinations of different combinations. Four hundred and nineteen patients with radiographically and biopsy-proven LAPC were prospectively enrolled. Factors associated with different strategies were analyzed with Chi-square test and contingency coefficients. Cox regression was used to identify factors predictive of survival...
May 17, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29770853/predominantly-cystic-clear-cell-renal-cell-carcinoma-and-multilocular-cystic-renal-neoplasm-of-low-malignant-potential-form-a-low-grade-spectrum
#16
Maria Tretiakova, Vikas Mehta, Masha Kocherginsky, Agata Minor, Steven S Shen, Sahussapont Joseph Sirintrapun, Jorge L Yao, Isabel Alvarado-Cabrero, Tatjana Antic, Scott E Eggener, Maria M Picken, Gladell P Paner
Multilocular cystic renal cell carcinoma has been recently excluded from clear cell renal cell carcinoma (CCRCC) category and re-designated as multilocular cystic renal neoplasm of low malignant potential (MCRNLMP) due to its uniformly good outcomes. While strict distinction between MCRNLMP from predominantly cystic CCRCC (pc-CCRCC) is being emphasized, the significance of extensive true cystic component in CCRCC has not been investigated. Herein, we analyzed 57 MCRNLMP, 69 pc-CCRCC, and 46 non-cystic CCRCC...
May 17, 2018: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/29770848/imaging-biomarkers-from-multiparametric-magnetic-resonance-imaging-are-associated-with-survival-outcomes-in-patients-with-brain-metastases-from-breast-cancer
#17
Bang-Bin Chen, Yen-Shen Lu, Chih-Wei Yu, Ching-Hung Lin, Tom Wei-Wu Chen, Shwu-Yuan Wei, Ann-Lii Cheng, Tiffany Ting-Fang Shih
OBJECTIVES: The aim of this study is to investigate the correlation of survival outcomes with imaging biomarkers from multiparametric magnetic resonance imaging (MRI) in patients with brain metastases from breast cancer (BMBC). METHODS: This study was approved by the institutional review board. Twenty-two patients with BMBC who underwent treatment involving bevacizumab on day 1, etoposide on days 2-4, and cisplatin on day 2 in 21-day cycles were prospectively enrolled for a phase II study...
May 16, 2018: European Radiology
https://www.readbyqxmd.com/read/29770630/survival-impact-of-low-anterior-resection-in-patients-with-epithelial-ovarian-cancer-grossly-confined-to-the-pelvic-cavity-a-korean-multicenter-study
#18
Miseon Kim, Dong Hoon Suh, Jeong Yeol Park, E Sun Paik, Seungmee Lee, Kyung Jin Eoh, Joo Hyun Nam, Yoo Young Lee, Jae Weon Kim, Sunghoon Kim
OBJECTIVE: To evaluate survival impact of low anterior resection (LAR) in patients with epithelial ovarian cancer (EOC) grossly confined to the pelvis. METHODS: We retrospectively reviewed 397 patients who underwent primary staging surgery for treatment of 2014 International Federation of Gynecology and Obstetrics (FIGO) stage II-IIIA EOC: 116 (29.2%) IIA, 212 (53.4%) IIB, and 69 (17.4%) IIIA. Patients with grossly enlarged retroperitoneal lymph nodes positive for metastatic carcinoma were excluded...
April 13, 2018: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29770619/impact-of-lymph-node-ratio-on-survival-in-stage-iiic-endometrioid-endometrial-cancer-a-turkish-gynecologic-oncology-group-study
#19
Ali Ayhan, Nazlı Topfedaisi Ozkan, Murat Öz, Günsu Kimyon Comert, Zeliha Firat Cuylan, Gonca Çoban, Osman Turkmen, Baki Erdem, Hanifi Şahin, Özgür Akbayır, Murat Dede, Ahmet Taner Turan, Husnu Celik, Tayfun Güngör, Ali Haberal, Macit Arvas, Mehmet Mutlu Meydanli
OBJECTIVE: The purpose of this study was to investigate the prognostic value of lymph node ratio (LNR) in women with stage IIIC endometrioid endometrial cancer (EC). METHODS: A multicenter, retrospective department database review was performed to identify patients with stage IIIC pure endometrioid EC at 6 gynecologic oncology centers in Turkey. A total of 207 women were included. LNR, defined as the percentage of positive lymph nodes (LNs) to total nodes recovered, was stratified into 2 groups: LNR1 (≤0...
March 13, 2018: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29769624/serial-minimal-residual-disease-mrd-monitoring-during-first-line-fcr-treatment-for-cll-may-direct-individualized-therapeutic-strategies
#20
Philip A Thompson, Christine B Peterson, Paolo Strati, Jeff Jorgensen, Michael J Keating, Susan M O'Brien, Alessandra Ferrajoli, Jan A Burger, Zeev Estrov, Nitin Jain, Tapan M Kadia, Gautam Borthakur, Courtney D DiNardo, Naval Daver, Elias Jabbour, William G Wierda
Achieving undetectable MRD (U-MRD) status after chemoimmunotherapy predicts longer progression-free and overall survival. The predictive factors and timing of relapse in patients with U-MRD and value of interim MRD analysis are ill-defined. This was a prospective study of 289 patients with CLL treated first-line with FCR. MRD analysis was performed after course 3 (C3) and at end of therapy (EOT) in bone marrow using 4-color flow cytometry (sensitivity 10-4 ). Eighteen percent of patients had U-MRD after C3 and 48% at EOT...
April 17, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
keyword
keyword
62483
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"